0001868279-22-000002.txt : 20221229 0001868279-22-000002.hdr.sgml : 20221229 20221229113951 ACCESSION NUMBER: 0001868279-22-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20221229 DATE AS OF CHANGE: 20221229 EFFECTIVENESS DATE: 20221229 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ArriVent Biopharma, Inc. CENTRAL INDEX KEY: 0001868279 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-469072 FILM NUMBER: 221497473 BUSINESS ADDRESS: STREET 1: 18 CAMPUS BLVD. STREET 2: SUITE 100 CITY: NEWTOWN SQUARE STATE: PA ZIP: 19073-3269 BUSINESS PHONE: 240-780-6356 MAIL ADDRESS: STREET 1: 18 CAMPUS BLVD. STREET 2: SUITE 100 CITY: NEWTOWN SQUARE STATE: PA ZIP: 19073-3269 D 1 primary_doc.xml X0708 D LIVE 0001868279 ArriVent Biopharma, Inc. 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA PENNSYLVANIA 19073-3269 240-780-6356 DELAWARE None None Corporation true 2021 Zhengbin (Bing) Yao c/o ArriVent BioPharma, Inc. 18 Campus Blvd., Suite 100 Newtown Square PA PENNSYLVANIA 19073-3269 Executive Officer Director Cong Xu c/o ArriVent BioPharma, Inc. 18 Campus Blvd., Suite 100 Newtown Square PA PENNSYLVANIA 19073-3269 Director Stuart Lutzker c/o ArriVent BioPharma, Inc. 18 Campus Blvd., Suite 100 Newtown Square PA PENNSYLVANIA 19073-3269 Director Jason Zhang c/o ArriVent Biopharma, Inc. 18 Campus Blvd., Suite 100 Newtown Square PA PENNSYLVANIA 19073-3269 Director Bahija Jallal c/o ArriVent BioPharma,Inc. 18 Campus Blvd., Suite 100 Newtown Square PA PENNSYLVANIA 19073-3269 Director Carl Gordon c/o ArriVent BioPharma, Inc. 18 Campus Blvd., Suite 100 Newtown Square PA PENNSYLVANIA 19073-3269 Director James Healy c/o ArriVent BioPharma, Inc. 18 Campus Blvd., Suite 100 Newtown Square PA PENNSYLVANIA 19073-3269 Director Biotechnology Decline to Disclose 06b false 2022-12-16 false true false 0 145000000 109999989 35000011 false 17 0 0 0 false ArriVent Biopharma, Inc. /s/ Zhengbin (Bing) Yao Zhengbin (Bing) Yao President and Chief Executive Officer 2022-12-29